Press Room

Press Clipping / Mar 06, 2022

Hovione promotes Herbeaux to CEO

C&EN, 6 March 2022

Hovione has appointed as CEO its chief operating officer, Jean-Luc Herbeaux, effective April 1. Herbeaux succeeds Guy Villax, who has been CEO of the family-owned pharmaceutical services company for 25 years. Herbeaux joined the firm in 2020. He previously held several management positions at the German chemical maker Evonik Industries, where his final role was head of the health-care business. In November, he and Villax outlined a $170 million investment program through 2023 that they said will increase Hovione’s production capacity by about 25%. Villax is credited with moving the company into the exclusive synthesis of active pharmaceutical ingredients (APIs) for drug industry customers. Hovione, one of several family-owned drug services companies in Europe, saw sales grow by 10 times under Villax’s stewardship. Major investments included the purchase of a Pfizer plant in Ireland in 2009. Villax says Hovione’s board chose to hire a nonfamily CEO in response to growth over the past 5 years. “When a company employs 1,600 or 1,700, you need skills that other people have much more developed than I have,” he tells C&EN. Hovione has about 2,000 employees.

 

Read the article on cen.acs.org and the full article (restricted content)

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024